NEW YORK, May 13, 2014 /PRNewswire/ -- IntelliCell
BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous stromal
vascular fraction cells (SVFCs) derived from the blood vessels
found in adipose tissue, announced today that Merril Hoge, former star NFL player and an
on-air analyst for ESPN, has joined its Board of Advisors.
According to Merril Hoge, "After
tearing a ligament in my elbow I tried to rehab it to avoid
surgery. During rehab I came across Dr. Victor and started to learn
more about Cell Therapy. After extensive research, I chose cell
therapy on my elbow, and thank goodness I did. I avoided surgery
and a year of rehab and now have a healthy, healed elbow. I am
excited to join IntelliCell's Board of Advisors and believe that I
can make a significant difference in helping other athletes."
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "I am honored that
Merril has joined our Board of Advisors. With his past career
in the NFL and his experiences of injuries to players from limb
injuries to concussions, he will bring a wealth of knowledge and
help lead IntelliCell to assist other professional athletes.
He is a perfect addition to our Board of Advisors that is lead by
Dr. James Andrews, our Chairman of
Cellular Orthopedic Sports Medicine. Also, we believe
Merril's ESPN on-air experience and reach will help us get our
message out to both professional and amateur athletes alike. We
believe that IntelliCell's Stromal Vascular Fraction Cells injected
locally into the site of injury will give hope to athletes for a
nonsurgical method to treat their orthopedic concerns."
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using adult
autologous stromal vascular fraction cells (SVFCs) derived from the
blood vessels in the adult adipose tissue. IntelliCell BioSciences
has developed its own patented technology and protocol to separate
adult autologous vascular cells from adipose tissue without the use
of enzymes. IntelliCell will also be seeking to develop
technology-licensing agreements with technology developers,
universities, and international business entities.
About Merril Hoge
Merril Hoge is an NFL analyst for
ESPN. These programs include NFL Live, NFL Matchup, NFL PrimeTime,
SportsCenter and NFL Countdown!
An eight-year NFL veteran, Hoge spent 1987-93 with the
Pittsburgh Steelers where he set the team record for most
receptions by a running back, totaling 50 in 1988 and was one of
only two Steelers to rush for more than 100 yards in back-to-back
playoff games, the other being Franco
Harris. He was Iron Man of the year 2 years in a row
and was named to the All Madden Team in 1990. He concluded his
career in 1995 with the Chicago Bears after suffering a series of
concussions. At the time of his retirement, Hoge had played in 122
consecutive games, the longest streak in the NFL at that time.
Outside of his television work, Hoge is Chairman of the Board of
the Highmark Caring Foundation, which is a center for grieving
children, adolescents and their families who have lost loved ones.
The foundation is particularly meaningful to Hoge, who lost his
mother when he was just 21 years old.
Hoge, who battled Non-Hodgkins Lymphoma in 2003, received the
Chairman's Advocacy Award from the Leukemia & Lymphoma Society
in 2004 and 2008 for his outstanding participation in driving
awareness for LLS and its mission. Hoge is also extremely
active in concussion research and in the prevention and treatment
of brain injuries. In the fall of 2009, Hoge testified at a
congressional hearing on head injuries in football, and in
January 2010, he was appointed to the
NFL MTBI Committee, which initiates research and advises the NFL on
the best practices for concussion prevention and management.
He also sat on the Board of USA
Football, where he feels he has his greatest impact on all the
youth that play the game of football.
September 2010, Hoge released his
first book, titled, "Find a Way: Three Words That Changed My Life".
The book is about his life philosophy that has helped guide him to
success and through many challenges.
Disclaimer: This press release contains anecdotal statements of
regarding cell therapy treatment. Treatment results experienced by
Mr. Hoge may not be indicative of results for other individuals in
other situations. Mr. Hoge's results are included to help
illustrate why he decided to join IntelliCell's Board of Advisors,
and not as evidence of effectiveness.
Forward-Looking Statements
Certain statements set forth in this press release constitute
"forward-looking statements." Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "will reach," "will change," "will soon," "should,"
"could," "would," "may," "can" or words or expressions of similar
meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the
company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
arhodes@intellicellbiosciences.com
(212) 249-3050
SOURCE IntelliCell BioSciences, Inc.